His primary scientific interests are in Internal medicine, Surgery, Oncology, Chemotherapy and Melanoma. As part of his studies on Internal medicine, he often connects relevant subjects like Gastroenterology. His Surgery research includes elements of Interferon and Subgroup analysis.
His Oncology research is multidisciplinary, relying on both Meta-analysis, Clinical trial, Proportional hazards model and Immunology. His biological study spans a wide range of topics, including Prospective cohort study and Pharmacology. His research investigates the connection with Melanoma and areas like Cancer which intersect with concerns in Cutaneous melanoma and Antigen.
His scientific interests lie mostly in Internal medicine, Oncology, Surgery, Gastroenterology and Melanoma. His work in Hazard ratio, Leukemia, Chemotherapy, Randomized controlled trial and Cancer are all subfields of Internal medicine research. His research in Hazard ratio tackles topics such as Decitabine which are related to areas like Azacitidine.
The study incorporates disciplines such as Myeloid leukemia and Immunology in addition to Oncology. He interconnects Survival rate, Vincristine, Acute lymphocytic leukemia and Asparaginase in the investigation of issues within Gastroenterology. His Melanoma course of study focuses on Adjuvant therapy and Meta-analysis.
Stefan Suciu mainly investigates Internal medicine, Oncology, Hazard ratio, Surgery and Placebo. His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology and Melanoma. Stefan Suciu combines subjects such as Survival rate, Idarubicin, Chemotherapy and Asparaginase with his study of Gastroenterology.
His Oncology research incorporates elements of Azacitidine and Myeloid leukemia, Immunology. His research integrates issues of Survival analysis, Randomized controlled trial, Proportional hazards model and Decitabine in his study of Hazard ratio. His work carried out in the field of Surgery brings together such families of science as Toxicity and Surrogate endpoint.
Internal medicine, Hazard ratio, Oncology, Surgery and Melanoma are his primary areas of study. His Placebo research extends to the thematically linked field of Internal medicine. His Hazard ratio research integrates issues from Decitabine, Proportional hazards model, Myelodysplastic syndromes, Randomization and Survival analysis.
In his research, Maintenance therapy and Vincristine is intimately related to Confidence interval, which falls under the overarching field of Oncology. His Surgery research includes themes of Gastroenterology and Toxicity. His work deals with themes such as Adjuvant and Alpha interferon, which intersect with Melanoma.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M.M. Eggermont;Christian U. Blank;Mario Mandala;Georgina V. Long.
The New England Journal of Medicine (2018)
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
Alexander M M Eggermont;Vanna Chiarion-Sileni;Jean-Jacques Grob;Reinhard Dummer.
The New England Journal of Medicine (2016)
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Alexander M M Eggermont;Vanna Chiarion-Sileni;Jean Jacques Grob;Reinhard Dummer.
Lancet Oncology (2015)
Autologous or Allogeneic Bone Marrow Transplantation Compared with Intensive Chemotherapy in Acute Myelogenous Leukemia
R. A. Zittoun;F. Mandelli;R. Willemze;T. De Witte.
The New England Journal of Medicine (1995)
Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia
Cavé H;van der Werff ten Bosch J;Suciu S;Guidal C.
The New England Journal of Medicine (1998)
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.
Alexander M. M. Eggermont;Stefan Suciu;Mario Santinami;Alessandro Testori.
The Lancet (2008)
Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
Michael Lübbert;Stefan Suciu;Liliana Baila;Björn Hans Rüter.
Journal of Clinical Oncology (2011)
On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group.
B Löwenberg;R Zittoun;H Kerkhofs;U Jehn.
Journal of Clinical Oncology (1989)
Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial.
Michel Duval;Stefan Suciu;Alina Ferster;Xavier Rialland.
Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial
Stefan Suciu;Franco Mandelli;Theo de Witte;Robert Zittoun.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: